Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $980.88 million. The enterprise value is $1.17 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 44.93 million shares outstanding. The number of shares has decreased by -1.02% in one year.
| Current Share Class | 44.93M |
| Shares Outstanding | 44.93M |
| Shares Change (YoY) | -1.02% |
| Shares Change (QoQ) | -2.20% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 106.69% |
| Float | 39.81M |
Valuation Ratios
The trailing PE ratio is 44.77 and the forward PE ratio is 5.95.
| PE Ratio | 44.77 |
| Forward PE | 5.95 |
| PS Ratio | 1.34 |
| Forward PS | 1.25 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 54.58 |
| EV / Sales | 1.63 |
| EV / EBITDA | 7.68 |
| EV / EBIT | 23.76 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.26, with a Debt / Equity ratio of 0.58.
| Current Ratio | 5.26 |
| Quick Ratio | 3.38 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.53 |
| Debt / FCF | n/a |
| Interest Coverage | 2.70 |
Financial Efficiency
Return on equity (ROE) is 2.90% and return on invested capital (ROIC) is 2.42%.
| Return on Equity (ROE) | 2.90% |
| Return on Assets (ROA) | 2.18% |
| Return on Invested Capital (ROIC) | 2.42% |
| Return on Capital Employed (ROCE) | 4.14% |
| Revenue Per Employee | $907,330 |
| Profits Per Employee | $27,137 |
| Employee Count | 790 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, PCRX has paid $20.39 million in taxes.
| Income Tax | 20.39M |
| Effective Tax Rate | 48.75% |
Stock Price Statistics
The stock price has increased by +22.11% in the last 52 weeks. The beta is 0.25, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +22.11% |
| 50-Day Moving Average | 24.35 |
| 200-Day Moving Average | 24.57 |
| Relative Strength Index (RSI) | 35.90 |
| Average Volume (20 Days) | 629,203 |
Short Selling Information
The latest short interest is 5.95 million, so 13.23% of the outstanding shares have been sold short.
| Short Interest | 5.95M |
| Short Previous Month | 6.28M |
| Short % of Shares Out | 13.23% |
| Short % of Float | 14.94% |
| Short Ratio (days to cover) | 11.23 |
Income Statement
In the last 12 months, PCRX had revenue of $716.79 million and earned $21.44 million in profits. Earnings per share was $0.47.
| Revenue | 716.79M |
| Gross Profit | 485.88M |
| Operating Income | 49.26M |
| Pretax Income | 41.83M |
| Net Income | 21.44M |
| EBITDA | 152.47M |
| EBIT | 49.26M |
| Earnings Per Share (EPS) | $0.47 |
Full Income StatementBalance Sheet
The company has $246.33 million in cash and $425.31 million in debt, giving a net cash position of -$178.97 million or -$3.98 per share.
| Cash & Cash Equivalents | 246.33M |
| Total Debt | 425.31M |
| Net Cash | -178.97M |
| Net Cash Per Share | -$3.98 |
| Equity (Book Value) | 727.21M |
| Book Value Per Share | 16.51 |
| Working Capital | 455.67M |
Full Balance SheetMargins
Gross margin is 67.79%, with operating and profit margins of 6.87% and 2.99%.
| Gross Margin | 67.79% |
| Operating Margin | 6.87% |
| Pretax Margin | 5.84% |
| Profit Margin | 2.99% |
| EBITDA Margin | 21.27% |
| EBIT Margin | 6.87% |
| FCF Margin | n/a |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.02% |
| Shareholder Yield | 1.02% |
| Earnings Yield | 2.16% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for PCRX is $32.40, which is 48.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.40 |
| Price Target Difference | 48.42% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 5.83% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
